Drug intelligence / Profile preview

P-042

Development stage: Preclinical
Lead developer: Pangea Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

P-042 is a pharmaceutical candidate currently in development by Pangea Pharmaceuticals, a company specializing in the reformulation and generic production of established therapeutic agents. P-042 is specifically targeted for use in ophthalmic examinations and the management of various eye conditions. Given Pangea's business model, P-042 is likely a proprietary formulation or a generic version of an existing diagnostic or therapeutic ophthalmic medication, such as a mydriatic, cycloplegic, or anesthetic agent, intended to improve clinical utility or patient outcomes during ocular assessments.

Beyond the preview

Go deeper on P-042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-042.

Explore the full profile